Pharmacokinetic properties of Gammagard Liquid 10% (KIOVIG) administered intravenously and subcutaneously to patients with primary immunodeficiency diseases (PID)

被引：0
|
作者：
Schiff, R., I [1 ]
Leibl, H. [1 ]
Engl, W. [1 ]
机构：
[1] Baxter Healthcare Corp, Westlake Village, CA USA
来源：
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2008年 / 154卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [31] Efficacy, Pharmacokinetics And Tolerability Of IQYMUNE®, A Novel 10% Intravenous Immunoglobulin (IVIg), In Patients With Primary Immunodeficiency(PID
    Krivan, Gergely
    Chernyshova, Ludmila
    Kostyuchenko, Larysa
    Lange, Andrzej
    Nyul, Zoltan
    Derfalvi, Beata
    Musial, Jacek
    Bellon, Anne
    Kappler, Martin
    Sadoun, Alain
    Puget, Sophie
    Bernatowska, Ewa
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 19 - 19
  • [32] Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
    Berger, Melvin
    Cunningham-Rundles, Charlotte
    Bonilla, Francisco A.
    Melamed, Isaac
    Bichler, Johann
    Zenker, Othmar
    Ballow, Mark
    JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) : 503 - 509
  • [33] Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases
    Melvin Berger
    Charlotte Cunningham-Rundles
    Francisco A Bonilla
    Isaac Melamed
    Johann Bichler
    Othmar Zenker
    Mark Ballow
    Journal of Clinical Immunology, 2007, 27 : 503 - 509
  • [34] Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency
    Church, Joseph A.
    Leibl, Heinz
    Stein, Mark R.
    Melamed, Isaac R.
    Rubinstein, Arye
    Schneider, Lynda C.
    Wasserman, Richard L.
    Pavlova, Borislava G.
    Birthistle, Karl
    Mancini, Marianne
    Fritsch, Sandor
    Patrone, Lisa
    Moore-Perry, Kerry
    Ehrlich, Hartmut J.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (04) : 388 - 395
  • [35] Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency
    Joseph A. Church
    Heinz Leibl
    Mark R. Stein
    Isaac R. Melamed
    Arye Rubinstein
    Lynda C. Schneider
    Richard L. Wasserman
    Borislava G. Pavlova
    Karl Birthistle
    Marianne Mancini
    Sandor Fritsch
    Lisa Patrone
    Kerry Moore-Perry
    Hartmut J. Ehrlich
    Journal of Clinical Immunology, 2006, 26 : 388 - 395
  • [36] Post-Authorization Safety Surveillance of KIOVIG (Human Normal Immunoglobulin 10% Liquid, Baxter) in an Open, Uncontrolled, Non-Interventional, Observational Cohort Study in Immunodeficiency and Autoimmune Diseases
    Misbah, S.
    Soler-Palacn, P.
    Mccoy, B.
    Engl, W.
    Empson, V.
    Nikolov, N.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S294 - S295
  • [37] PRIMARY IMMUNODEFICIENCY DISEASES (PID) PRESENTING AS LYMPHOMA AND TREATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): DESCRIPTIONS OF 6 PATIENTS
    Aabideen, K.
    Gupta, V.
    Nademi, Z.
    Slatter, M.
    Hambleton, S.
    Gennery, A.
    Flood, T.
    Abinum, M.
    Cant, A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S316 - S316
  • [38] Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
    Wasserman, Richard L.
    Church, Joseph A.
    Stein, Mark
    Moy, James
    White, Martha
    Strausbaugh, Steven
    Schroeder, Harry
    Ballow, Mark
    Harris, James
    Melamed, Isaac
    Elkayam, David
    Lumry, William
    Suez, Daniel
    Rehman, Syed M.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (04) : 663 - 669
  • [39] Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
    Richard L. Wasserman
    Joseph A. Church
    Mark Stein
    James Moy
    Martha White
    Steven Strausbaugh
    Harry Schroeder
    Mark Ballow
    James Harris
    Isaac Melamed
    David Elkayam
    William Lumry
    Daniel Suez
    Syed M. Rehman
    Journal of Clinical Immunology, 2012, 32 : 663 - 669
  • [40] Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors
    Mary Johansen
    Thomas Zukowski
    Paulo M. Hoff
    Robert A. Newman
    Dan Ni
    Toni Hutto
    James Abbruzzeese
    Elmer Berghorn
    Frederick Hausheer
    Timothy Madden
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 370 - 376
12345